The largest study on post-allogeneic hematopoietic cell transplant lymphoproliferative disorder (PTLD) epidemiology showed a cumulative incidence of 1.7% in patients receiving antithymocyte globulin (ATG). We had noted an apparently higher incidence in our transplant recipients whose conditioning included ATG. Therefore, we formally determined the incidence of PTLD through chart review. We also evaluated whether counts of EBV-specific T lymphocytes measured by cytokine flow cytometry could identify patients at risk of developing PTLD. Among 307 allogeneic transplant recipients, 25 (8.1%) developed PTLD. This was biopsy proven in 11 patients, and was fatal in seven patients. Patient age, EBV serostatus, donor type/match or GVHD did not influence PTLD risk significantly. Median onset of PTLD was 55 (range, 28-770) days post transplant. Day 28 EBV-specific T lymphocyte counts were not significantly different in 11 patients who developed PTLD and 31 non-PTLD patients matched for published risk factors for PTLD. In summary, when using conditioning with thymoglobulin 4.5 mg/kg, the incidence of PTLD is relatively high and cannot be predicted by day 28 cytokine flow cytometry-determined EBV-specific T lymphocyte counts. Thus, in this scenario PTLD prevention may be warranted, for example, using EBV DNAemia monitoring with preemptive therapy.
Introduction
T lymphocyte depletion ex vivo or in vivo for prophylaxis of GVHD in hematopoietic cell transplant (HCT) recipients has been associated with an increased incidence of post transplant lymphoproliferative disorder (PTLD).
1 PTLD typically arises from memory B lymphocytes infected with EBV. 2 EBV is a g-herpesvirus that is present in 490% adults. 3, 4 It is typically clinically silent in immunocompetent individuals. 5 After HCT, when patients are immunocompromised, EBV may reactivate and induce PTLD. EBV has been shown to reactivate in B67% of patients receiving antithymocyte globulin (ATG) for in vivo T lymphocyte depletion for GVHD prophylaxis. 6 The proportion of patients with EBV reactivation who develop PTLD is unknown.
The reported incidence of PTLD has ranged from 0.2% with no T lymphocyte depletion to 71% with extremely potent T lymphocyte depletion. 1, [6] [7] [8] [9] [10] [11] [12] In the largest study to date, which included 26 901 allogeneic HCT recipients, the cumulative incidence of PTLD was 0.2% with no T-cell depletion, 2.8% with selective (B lymphocyte sparing) T lymphocyte depletion of grafts ex vivo and 1.7% in patients receiving ATG as in vivo T lymphocyte depletion for GvHD prophylaxis or treatment. 1 In the published studies, diagnostic criteria for PTLD and strategies for its prevention varied or were not described. These criteria are important when determining the incidence of PTLD, as PTLD is a heterogeneous group of disorders ranging from relatively benign polyclonal hyperplasia to malignant lymphoma. It can be proven only by biopsy. 13 Risk factors for the development of PTLD include use of unrelated or HLA-mismatched related donors, selective T lymphocyte depletion, high recipient age and acute GVHD (aGVHD) and chronic GVHD (cGVHD). 1 A number of treatment strategies for PTLD exist. These range from tapering immunosuppressive drugs or administering rituximab to infusion of donor lymphocytes, either unselected or enriched for EBV-specific T lymphocytes. 50 and 100%, although it is not always clear whether PTLD was the primary or secondary cause of death, or an incidental finding at autopsy. 7, 10, 11, 16 Mortality rates appear to be lower if intervention (tapering immunosuppression or administering rituximab or donor lymphocytes) occurs prophylactically (at a specified post transplant time point, irrespective of EBV reactivation) or preemptively (at the time of EBV viremia exceeding a threshold) rather than after PTLD has been diagnosed. 15 However, prophylactic or preemptive intervention subjects patients who would not develop PTLD to the side effects and costs of the intervention.
Identifying patients at high risk of PTLD would be useful for restricting prophylactic or preemptive intervention only to patients who are likely to need the intervention. Associations between presence of EBV-specific T lymphocytes and ability to control EBV reactivation 17 or PTLD 18, 19 have been described. Also, infusion of functional (IFNg-secreting) EBV-specific T lymphocytes has been shown to prevent PTLD.
14 This suggests that low counts of functional EBV-specific T lymphocytes may be associated with the risk of developing PTLD, and could therefore represent a useful predictive marker.
We noted a number of patients who developed PTLD after our standard ATG-containing conditioning regimen (4.5 mg/kg of thymoglobulin), in whom no PTLD prophylaxis or EBV viremia monitoring/preemptive intervention was instituted. This prompted us to formally determine the PTLD incidence through chart review. The earliest PTLD was diagnosed on day 28, consistent with Landgren's study showing that none of 127 PTLD's developing among 26 901 patients was diagnosed in the first month post transplant. A significant fraction of our patients had blood mononuclear cells (MNCs) cryopreserved on day 28. This allowed us to evaluate whether EBV-specific T lymphocyte counts on day 28 could predict patients likely to develop PTLD.
Patients and methods
Patients and transplantation A total of 311 consecutive patients, whose conditioning included ATG, received a first allogeneic marrow or filgrastim-mobilized blood SCT in Calgary between January 2004 and January 2009. Four patients were excluded as they died or relapsed before day 28, leaving 307 evaluable patients. Charts were reviewed to determine the incidence of PTLD. Patients were followed for death until death or last contact, whichever occurred first. Patients were followed for PTLD until death, last contact or an event typically treated with chemotherapy, donor lymphocyte infusion or second HCT, whichever occurred first. Events typically treated with chemotherapy, donor lymphocyte infusion or second HCT were relapse, graft failure or second malignancy (including PTLD, and excluding non-melanoma skin cancer and carcinoma in situ of any organ). The median follow-up for death was 397 days (range, 29-1727), and for PTLD it was 375 days (range, 28-1727). The minimum follow-up for death, excluding patients who died, was 365 days, and for PTLD, excluding patients who died, relapsed or developed graft failure or second malignancy, was 370 days. Thus, given that the vast majority of PTLDs in published studies have occurred during the first year post transplant, our cohort was sufficiently mature for the evaluation of PTLD incidence and PTLD-associated mortality.
Conditioning was typically with fludarabine (250 mg/m 2 ), busulfan (12.8 mg/kg intravenously) and ATG, and additional GVHD prophylaxis with methotrexate on day 1, 3, 6 and 11 and cyclosporine from day À1 until 3 to 6 months post transplant (longer in case of cGVHD needing systemic therapy). 20 Conditioning of some patients included TBI (4 Gy). 21 All patients received rabbit-ATG (thymoglobulin, Genzyme, Mississauga, Ontario, Canada) 0.5 mg/kg on day À2, 2.0 mg/kg on day À1 and 2.0 mg/kg on day 0 (total, 4.5 mg/kg). 20 Table 1 displays patient and donor characteristics. Supportive care was similar for all patients. All blood products were from CMV seronegative donors and were irradiated and leukocyte depleted. No antibacterial or antifungal prophylaxis was given routinely (except for trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis). Pneumocystis prophylaxis, typically using trimethoprim-sulfamethoxazole, was given until 6 months post transplant or longer (in case of cGVHD needing systemic therapy). Acyclovir, typically 400 mg orally twice a day, was used until 6-12 months post transplant or longer (in case of cGVHD needing systemic therapy). Monitoring of EBV DNAemia was not carried out. aGVHD and cGVHD were diagnosed according to historical criteria (acute if onset by day 100, chronic if present after day 100). aGVHD was graded according to the 1994 consensus conference. 22 Grade 1 aGVHD was not treated or treated with only topical immunosuppressive medications. Grade 2-4 aGVHD was treated with systemic immunosuppressive medications (typically prednisone or methylprednisolone). cGVHD was graded as none, not needing systemic therapy ('cGVHD NNST', roughly corresponding to mild cGVHD per National Institutes of Health staging 23 ) or needing systemic therapy ('cGVHD NST', roughly corresponding to moderate or severe cGVHD per the National Institutes of Health staging). The need for systemic therapy was determined by attending physicians. Patients were considered treated (rather than prophylaxed) with systemic immunosuppressive drugs if cyclosporine was given beyond 6 months and/or additional immunosuppressive drug(s) was (were) given at any time after 3 months post transplant for the treatment of cGVHD. The study was approved by the University of Calgary Research Ethics Board.
PTLD definition and classification
We used a modified World Health Organization (WHO) definition and classification. 24 Proven PTLD was defined as histologically diagnosed PTLD. In patients with pretransplant diagnosis of lymphoma, positive in situ hybridization for EBV-encoded RNA was also required. Probable PTLD was defined as typical clinical manifestation(s) of PTLD (unexplained fever, lymphadenopathy, splenomegaly, lymphocytosis or imaging-diagnosed mass), with EBV DNAemia above 400 copies per mg blood DNA (no patient in our study with proven or suspected PTLD had lower DNAemia). Reasons for not performing biopsy of probable PTLD included logistics (overbooked surgery schedule) or relative inaccessibility of the lesion.
EBV serostatus and DNAemia EBV serostatus was determined before transplantation in both donor and recipient using enzymoimmunoassay for EBV nuclear antigen (EBNA) IgG or EBV viral capsid antigen IgG (Trinity Biotech Captia, Bray, Ireland).
EBV DNAemia was determined by an in-house assay (developed by XL Pang and J Preiksaitis Alberta Health Services, Calgary, AB, Canada). Total DNA was extracted from 200 ml of whole blood and then normalized to 25 mg/ ml. Ten ml of DNA (0.25 mg) was amplified using LightCycler (Roche Diagnostic, Toronto, Ontario, Canada) real-time quantitative PCR with primers and hybridization probes targeting EBNA1 gene. EBV DNAemia was quantified against a standard curve. The limit of detection of the assay is 20 copies per mg blood DNA and the limit of quantification is 60 copies per mg blood DNA.
Selection of patients for EBV-specific T lymphocyte enumeration
Cryopreserved blood MNCs from day 28 were available on 11 of the 25 patients who developed PTLD, and on 150 of 282 patients who did not develop PTLD. For each of the 11 PTLD case patients, we attempted to select three non-PTLD control patients matched according to the following criteria: (1) alive without relapse, graft failure or second malignancy at 90 days after the post transplant day on which the case patient developed PTLD (to give the control patients sufficient time to develop PTLD); (2) received transplant from a similarly matched donor (HLA-matched sibling, 10/10 allele-matched unrelated donor or o10/10 allele-matched unrelated donor); (3) did or did not develop significant GVHD (grade 2-4 aGVHD or cGVHD needing systemic therapy) by the post transplant day on which the case patient developed PTLD; and (4) both donor and recipient EBV seropositive, as all case patients and their donors were EBV seropositive. When more than three control patients were available per the above criteria for a case patient, we selected the three control patients whose age was the closest to that of the case patient. We found three control patients for nine case patients and only two control patients for two case patients; hence, the total number of control patients studied was 31. The median number of stored MNCs per patient was 77.5 million (range 6-230 million).
Enumeration of EBV-specific T lymphocytes
MNCs were thawed and rested for 2 h in complete media (RPMI1640 supplemented with 2 mM L-glutamine, 100 U/ ml penicillin and 0.1 mg/ml streptomycin (Sigma, Toronto, ON, Canada) and 10% fetal bovine serum). Median recovery rate of viable (trypan blue excluding) MNCs was 55% (range 20-100%). One million MNCs were stimulated in the presence of 2.5 mg/ml CD28 (BD Bioscience, Toronto, ON, Canada) in a final volume of 0.5 ml complete media. As stimuli, we used overlapping 15-mer peptide pools of from EBV proteins (BZLF1, EBNA3A þ EBNA3B þ EBNA3C, or LMP1 þ LMP2, purchased from JPT, Berlin, To analyze IL2, TNFa and IFNg production, we incubated the MNCs for 18 h total, the last 16 h in the presence of 35 ml of 1:43 dilution of brefeldin A (Golgiplug, BD Bioscience). Cells were washed with PBS containing 1% fetal bovine serum and 0.1% sodium azide, and then fixed and permeabilized using the Cytofix/Cytoperm kit from BD Bioscience according to the manufacturer's instructions. Cells were stained in the dark for 30 min at 4 1C, and washed with PBS containing 1% fetal bovine serum and 0.1% sodium azide. The following fluorochrome-labeled antibodies were used for staining: FITC-TNFa, APC-IL2, PC7-IFNg, eFluor605-CD8, eFluor450-CD4 (all from eBioscience, San Diego, CA, USA). Alexa700-CD3 was obtained from BD Biosciences (San Jose, CA, USA). Flow cytometric data acquisition was performed on a FACSAria (BD Biosciences). A total of 150 000 CD3 þ CD4 þ cells were acquired whenever possible. Enumeration of T lymphocyte subsets was performed using the FACSDIVA software (BD Biosciences). First, lymphocytes were gated on a forward vs side scatter plot. Subsequently, CD3 þ CD4 þ CD8À or CD3 þ CD4ÀCD8 þ cells were gated. Thereafter, cells producing IL2, TNFa and/or IFNg (each cytokine alone or in combination) were gated and their percentages enumerated (Supplementary Figure 1) . Background percentages from HIVgag peptide-stimulated cells were subtracted. Absolute counts were determined using absolute lymphocyte counts obtained from a routine hematology laboratory.
Statistics PTLD and no PTLD patient groups were compared using the w 2 test for categorical variables and Mann-WhitneyWilcoxon rank-sum test for continuous variables.
Results

PTLD incidence and risk factors
Twenty-five of the 307 patients developed PTLD (cumulative incidence, 8.1%). The PTLD was proven in 11 patients and probable in 14 patients (Table 2 ). There were no significant differences between the PTLD and no PTLD groups in clinical/demographic characteristics previously identified as risk factors for developing PTLD (patient age, donor type/HLA match, donor/recipient EBV serostatus, aGVHD grade 2-4 or cGvHD needing systemic therapy) ( Table 1) . Of the patients who developed PTLD early (before day 100), most developed it in the setting of grade 0-1 aGVHD (18/22 patients) and only few developed it in the setting of grade 2-4 aGVHD treated with systemic immunosuppressive therapy (4/22 patients). All patients who developed late PTLD (after day 100, n ¼ 3) were on immunosuppressive therapy for cGvHD at the time of developing PTLD. Of the seven patients who developed PTLD in the setting of aGVHD or cGVHD, four had been treated for steroid-resistant GVHD with ATG.
PTLD developed at median post transplant day 55.5 (range, 28-770). The median peak EBV titer was 64 840 copies per mg DNA (range, 450-704 000).
Among the 11 patients with proven PTLD, seven were monomorphic and four were polymorphic ( Table 2 ). Five of the 11 patients died as they had monomorphic PTLD.
Of the 25 PTLD patients, seven died with PTLD (presumably due to PTLD) and five died due to other causes after complete resolution of PTLD (three patients without relapse and two patients with relapse of the hematological malignancy that was treated with HCT). 
EBV-specific T lymphocytes
We next evaluated whether the percent or absolute count of a subset of functional (cytokine-producing) EBV-specific T lymphocytes could identify patients subsequently developing PTLD. The 11 PTLD patients and the 31 no PTLD controls were compared for the day 28 percents and absolute counts of each of 56 EBV-specific T lymphocyte subsets, that is, BZLF1-specific CD4T lymphocytes, BZLF1-specific CD8T lymphocytes, EBNA3A/B/C-specific CD4T lymphocytes, EBNA3A/B/C-specific CD8T lymphocytes, LMP1/2-specific CD4T lymphocytes and LMP1/2-specific CD8T lymphocytes; for each of these cell types, the following seven subsets were enumerated: producing IFNg and not TNFa or IL2, producing TNFa and not IFNg or IL2, producing IL2 and not IFNg or TNFa, producing both IFNg and TNFa (and not IL2), producing both IFNg and IL2 (and not TNFa) producing both TNFa and IL2 (and not IFNg), and producing all three cytokines. There was no significant difference in the percents or absolute counts of any of the subsets or combination of subsets between the PTLD patients and no PTLD controls ( Figure 1 ). The main reason for the lack of statistical difference appeared to be the overall low number of EBVspecific T lymphocytes at this early post transplant time point (most PTLD patients as well as most no PTLD controls had undetectable EBV-specific T lymphocytes of any subset). Nevertheless, there was a trend toward higher absolute counts of BZLF1-, EBNA3A/B/C-and LMP1/2-specific T lymphocytes in the no PTLD controls compared with the PTLD patients (Figure 1b ). There also was no difference in absolute lymphocyte counts ( Figure 2 ).
Discussion
We studied 307 ATG-conditioned patients, of which 25 (8.1%) developed PTLD. The discrepancies in PTLD occurrence between our study and previous reports 1, 7, 9, 12 are likely a result of differences in patient populations studied, use of different T lymphocyte depletion methods and differences in diagnosing/defining PTLD. The highest occurrence of PTLD was found in the study of Meijer et al. 12 (5/7, that is, 71%), in which both ex vivo-selective T lymphocyte depletion of the graft and ATG administration with conditioning were used. Chiang et al. 7 used both ex vivo-selective T lymphocyte depletion of the graft and in vivo ATG given post transplant (not with conditioning), and reported the occurrence of PTLD of 6%. Finke et al. 9 used only in vivo ATG with conditioning, and reported PTLD occurrence of 5%. Of note, Finke et al. 9 used a different type of ATG (rabbit-anti-Jurkat T-cell line globulin, whereas we used rabbit-ATG). Also worth noting in the study of Finke et al. 9 was that participating centers were allowed to use a prevention strategy for PTLD, which may in part explain why their occurrence of PTLD was lower than in our study in which no PTLD prevention 1 reported PTLD occurrence of 0.2% with no T-cell depletion, 2.8% with selective T lymphocyte depletion ex vivo and 1.7% in patients receiving ATG during conditioning or after transplant. The lower occurrence of PTLD in patients receiving ATG in Landgren's study compared with our study may be a consequence of under-reporting to the registry. It may also be due to the fact that in the period covered by Landgren's study , horse-antihuman thymocyte globulin was typically used, whereas we used rabbit-anti-human thymocyte globulin. The horsederived ATG may have a lower potency to cause PTLD than the rabbit-derived ATG. 27 The definitions of PTLD have varied among studies, and this obviously leads to differences in occurrences. A certain diagnosis of PTLD can only be made by pathological evaluation of affected tissue. However, this is not always obtained, especially if sites are not easily amenable to biopsy and in mild cases where patients respond to a decrease in immunosuppression. In our study, we had 11 biopsy-verified cases and 14 probable cases. The true occurrence of PTLD may therefore be somewhere between 3.6 and 8.1%. This is still higher than that reported by Landgren et al. 1 However, Landgren et al. 1 included only marrow recipients, whereas most of our patients received blood stem cells. Perhaps, patients receiving blood stem cells are at higher risk, because compared with marrow grafts, blood stem cell grafts contains 410-fold more memory B lymphocytes, 28 which are the main reservoir of EBV. 2 We did not find a higher PTLD risk for patients receiving blood stem cells vs marrow, although our study only included a small number of patients receiving marrow.
The time from transplant to PTLD diagnosis in our study was relatively short (median 55 days), and 22/25 (88%) PTLDs occurred in the first 100 days post transplant. This contrasts with Landgren's study in which only 48/107 (45%) PTLDs occurring within 1-year post transplant among total patients (both who did and did not receive ATG) occurred in the first 3 months. This may be due, in part, to the fact that ATG was not used in the majority of transplants reviewed by Landgren et al. 1 However, even among patients who received ATG, the occurrence of early PTLD appeared lower than in our study-only 23/37 (62%) PTLDs in Landgren's study occurring within 1-year post transplant occurred in the first 3 months. This may be due, in part, to the fact that in Landgren's study ATG was not always administered during conditioning (sometimes it was administered only post transplant for GVHD treatment), whereas in our study ATG was administered always during conditioning. The earlier onset of PTLD in our compared with Landgren's study cannot be due to a short follow-up in our study, as the minimum follow-up for PTLD when excluding patients who died, relapsed or developed graft failure or second malignancy was 370 days. The early onset of most PTLD's in our study and the fact that all 3 post-day 100 PTLD's in our study occurred in the setting of cGVHD needing systemic therapy are consistent with Landgren's findings that ATG administration or ex vivo-selective T-cell depletion are the major risk factors for early PTLD, whereas cGVHD or its treatment is the major risk factor for late PTLD.
Reported mortality rates due to PTLD among patients developing PTLD range from 10-40% to 85% 16 depending on treatment strategy, with EBV-specific T lymphocyte transfers associated with the lowest mortality and reduction in immunosuppression alone with the highest mortality. 15 Most PTLD patients in our series were treated with rituximab, and 7/25 died due to PTLD. This is consistent with published reports of the response rates to rituximab. [29] [30] [31] [32] Administration of rabbit-anti-human T lymphocyte antibodies has been increasingly used by transplant programs because the antibodies can partially prevent aGVHD and cGVHD without impacting rates of relapse and non-EBV infections (except when used at a high dose, for example, 48 mg/kg thymoglobulin). 9, 20, [33] [34] [35] [36] [37] [38] [39] [40] [41] Thus, our findings that in patients conditioned with rabbit-ATG, the PTLD occurrence is relatively high (8.1%) and that the vast majority of PTLD's occurring before day 100 are important. This suggests that monitoring EBV DNAemia in the first 100 days is warranted, together with preemptive (at the time of high/rising EBV DNAemia) or prompt (early in the course of PTLD) administration of rituximab- [42] [43] [44] or EBV-specific T lymphocytes. 2, 14, 45, 46 This is in support of current guidelines. 47, 48 In our cohort, the PTLD-associated mortality was 2.3-3.9%. This may be the 'price' one has to pay for lower likelihood of aGVHD and cGVHD when using ATG-based conditioning without post transplant EBV DNAemia monitoring/preemptive therapy. The 'price' may be lower with post transplant EBV DNAemia monitoring/preemptive therapy; this should ideally be evaluated in a randomized study.
Finally, we wished to determine whether the count of functional EBV-specific T lymphocytes could predict patients who subsequently developed PTLD. Given that PTLD occurs in T lymphocyte-deficient patients and that EBV DNAemia after HCT declines concurrently with increasing EBV-specific T-cell counts, [17] [18] [19] T lymphocyte control of EBV-infected B lymphocytes is important. 49 Previous studies have measured EBV-specific T cells at time points after the median day of onset of PTLD. We therefore wished to determine if EBV-specific T lymphocytes at a predefined post transplant time point before the development of PTLD could predict patients at risk. We Post transplant lymphoproliferative disorder M Hoegh-Petersen et al choose to enumerate functional (capable of producing cytokines) EBV-specific T lymphocytes on day 28. Disappointingly, we found that EBV-specific T lymphocyte counts or function have not recovered enough by day 28 to enable the enumeration of functional EBV-specific T lymphocytes. Nevertheless, we found an overall trend of higher BZLF1-, EBNA3A/B/C-and LMP1/2-specific CD8T lymphocyte counts in patients who did not develop PTLD (Figure 1b ).
In conclusion, we have found that the occurrence of PTLD in patients receiving mostly blood stem cells in the setting of in vivo T lymphocyte depletion with ATG is probably approximately 8% and that in this setting the transplant mortality associated with PTLD is approximately 2-4%. There were no patient characteristics that were significantly associated with the development of PTLD in our relatively small cohort, and the presence of EBV-specific T lymphocytes determined by cytokine flow cytometry at day 28 could not discriminate between patients who subsequently did vs who did not develop PTLD. Further studies should attempt to identify patients at risk (to restrict preemptive therapy to only those who need it) using ELISPOT-measured EBV-specific T-cell counts, EBV DNAemia and/or serum ATG levels. 41 
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